drugset / Trial / NCT02672267

A Study of Allogeneic Low Oxygen Mesenchymal Bone Marrow Cells in Subjects With Myocardial Infarction

NCT02672267

Phase 3 Completed 50 enrolled Altaco XXI, LLP Duke University · collab
RandomizedParallel-groupSingle-blindTreatment

Summary

The purpose of this study is to assess the safety, tolerability and preliminary efficacy of human allogeneic ischemia tolerant mesenchymal bone marrow cells (aLoOxMBMC) administered intravenously to subjects with Acute Myocardial Infarction (STEMI, non STEMI).

Timeline

Start
2014-07
Primary completion
2016-04
Completion
2016-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Rexlemestrocel-L Cell therapy Intravenous

Indications